VivoSim Receives $5 Million Milestone Payment from Eli Lilly and Forecasts Over 500% Revenue Growth in FY2027

VivoSim received a $5 million milestone payment from Eli Lilly following the initiation of Phase 2 trials for an inflammatory bowel disease drug candidate previously sold to the pharmaceutical company. The company also projected more than 500% revenue growth in fiscal 2027, driven by increased adoption of its New Approach Methodologies (NAM) contract research services.

By Fiona Craig Wed, July 15, 2026 at 5:46 PM GMT+3 3 min read · Yahoo Finance · July 15, 2026, 14:46 UTC

Tickers: $LLY

Topics: milestone payment pharmaceutical partnership revenue growth forecast

Read the full article at Yahoo Finance

More World news

Suburban Propane Partners Outlines $60M-$70M Capital Expenditures for Fiscal 2027 Seeking Alpha · November 12, 2026, 17:00 UTC
Nvidia, Supermicro, and Megaspeed Face U.S. Department of Justice Probes Seeking Alpha · November 12, 2026, 17:00 UTC
Starbucks Implements Quarterly Performance-Based Bonuses for Baristas Seeking Alpha · November 12, 2026, 17:03 UTC
Jim Cramer Analyzes Nvidia Leadership Transition and Recommends AMD, Constellation Brands, and Kimberly-Clark CNBC · November 12, 2026, 16:55 UTC
Nvidia CEO Jensen Huang Resigns Amid Personal Scandal, Threatening $500 Billion AI Financing Plan CNBC · November 12, 2026, 16:55 UTC
Al Mouj Muscat Receives Three Architectural Awards at International and Arabian Property Awards 2026 PR Newswire · November 12, 2026, 17:01 UTC
SoftBank Reports $7.1 Billion Quarterly Loss Driven by Natural Gas Turbine Over-Ordering TechCrunch · November 12, 2026, 17:00 UTC
PayPal and Kiva Renew Long-Term Partnership to Support Global Microloans PR Newswire · November 12, 2026, 17:00 UTC
Tesla to Discontinue Cybertruck Production by Summer 2027 to Prioritize Cybercab The Verge · November 12, 2026, 17:00 UTC
Absci Reports Q3 2026 Financial Results and Clinical Updates for ABS-201 Motley Fool · November 12, 2026, 16:54 UTC